Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity-based kinase profiling of approved tyrosine kinase inhibitors.

Genes to cells : devoted to molecular & cellular mechanisms - 1 Feb 2013

Kitagawa Daisuke, Yokota Koichi, Gouda Masaki, Narumi Yugo, Ohmoto Hiroshi, Nishiwaki Eiji, Akita Kensaku, Kirii Yasuyuki

Abstract excerpt

The specificities of nine approved tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, and pazopanib) were determined by activity-based kinase profiling using a large panel of human recombinant active kinases. This panel consisted of 79 tyrosine kinases, 199 serine/threonine kinases, three lipid kinases, and 29 disease-relevant mutant kinases. Many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Enzyme Activation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Kinetics

Share to Protein Kinase Inhibitors

Share to Protein Kinases

Share to Proteome

Share to Reproducibility of Results

Source

Identifiers

PMID: 23279183
DOI: 10.1111/gtc.12022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity-based kinase profiling of approved tyrosine kinase inhibitors.PMID 23279183Read ↗

Kinase-targeted cancer therapies: progress, challenges and future directionsSemantic proximity Read ↗

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future PerspectivesSemantic proximity Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020Semantic proximity Read ↗

Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.Semantic proximity Read ↗

Protein Kinases as Targets for Cancer TreatmentSemantic proximity Read ↗

Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase InhibitorsSemantic proximity Read ↗

The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistanceSemantic proximity Read ↗

A structural atlas of kinases inhibited by clinically approved drugs.Semantic proximity Read ↗

The kinase polypharmacology landscape of clinical PARP inhibitorsSemantic proximity Read ↗

Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.